**PaO2/FiO2 in 72h for ARDS patients**

**Patient or population:** patients with ARDS patients

**Settings:**

**Intervention:** PaO2/FiO2 in 72h

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of Participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>PaO2/FiO2 in 72h</td>
<td>Control: PaO2/FiO2 in 72h</td>
<td>12.27 higher (4.65 to 19.89 higher)</td>
<td>1437 (4 studies)</td>
<td>low(^1)</td>
<td></td>
</tr>
</tbody>
</table>

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CT: Confidence interval;

**GRADE Working Group grades of evidence**

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

\(^1\) The results of the four studies were not consistent

\(^2\) No more than 150 patients were included in two trials

---

*Supplemental Table 5* GRADE system: PaO2/FiO2 at 72hrs for ARDS patients